secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001645113-24-000002
Event type: leadership
Sentiment:  positive
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure appoints Dr. Nicolas Leupin as CMO; Pritesh Shah steps down as executive officer
--------------------------------------------------------------------------------

- Dr. Nicolas Leupin appointed CMO, overseeing medical affairs, safety, and clinical development.
- Pritesh Shah resigns as executive officer; to serve as Senior Advisor to CEO through June 30, 2025.
- Frank Leonard appointed EVP and President, Novocure Oncology; base salary $525,000, target bonus 60%.
- Shah's salary drops from $500k to $120k after June 2024; equity grants continue vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000002/0001645113-24-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000002/nvcr-20240104.htm
  HTML page:      https://secwatch.observer/filing/0001645113-24-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer